Purchase this article with an account.
Marcia Clivati Martins, Vanessa Cordeiro Storti, Natalia Abujamra, Erico Pacheco, Nicolau Homar, Rafael Andrade Leal, Gulherme Naves Borges, Adle Saulo Nogueira, Anna Carolina Carvalho Araujo, Arnaldo Furman Bordon; SHORT-TERM VARIATION OF MACULAR THICKNESS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR DIABETIC MACULAR EDEMA. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2103.
Download citation file:
© 2017 Association for Research in Vision and Ophthalmology.
To evaluate the short-term variation of central macular thickness (CMT) after intravitreal bevacizumab injection for diabetic macular edema.
A prospective observational clinical study was performed. Written informed consent was obtained for every patient. Study was approved by the Ethics Committee number 35463914.2.0000.0088. Trial was registered at EudraCT number 2015-005516-15. Assessment for best corrected visual acuity (BCVA) was performed at baseline and 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab. Complete ophthalmic examination including fundus biomicroscopy and optical coherence tomography central macular thickness using Spectralis (Heidelberg Engineering) were performed at baseline and 1 hour, 4 hours, 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab.
A total of 16 eyes of 12 patients (6 male; mean age, 62 ± 8.7 years; range, 50-74 years) who completed the 28-day follow-up were included for analysis. Mean CMT at baseline was: 551 ± 219.38μm; Mean CMT at 1 hour, 4-hour, 24-hour, 3-day, 7 day, 14-day, 21-day, and 28-day were: 543 ± 217μm, 531 ± 217μm, 505 ± 189μm, 473 ± 153μm, 475 ± 150μm, 453 ± 137μm, 466 ± 169μm, and 465 ± 164μm, respectively.Statistically significant reduction of CMT compared to baseline was found at the 4-hour follow-up (mean CMT reduction: t=3.6389, p < 0.01), and lasted until the 28-day follow-up (mean CMT reduction: t=2.1453, p < 0.05). Improvement in mean BCVA was observed in the 24-hour follow-up and lasted until the 28-day follow-up although it was not statistically significant.
Bevacizumab produced improvement in CMT as soon as 4-hour after injection that persists up to 28 days. However, visual acuity did not reached statistical significance level, probably due to the sample size.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only